C000156862 Fees and Costs — Allspring Dynamic Target 2015 Fund, Class C

Data updated: 2024-01-26

The net expense ratio is 1.34% (2.23% before fee waivers). This share class carries a deferred sales charge of up to 1.00%. In fiscal 2023 the fund paid $4K in broker commissions, 0.0247% of average net assets, and portfolio turnover was 87%.

C000156862 Fees and Expenses

Annual operating expenses and sales charges of C000156862. Prospectus, as of June 30, 2023.

Annual operating expenses
Management fee0.10%
12b-1 fee0.75%
Other expenses1.28%
Gross expense ratio2.23%
Fee waiver−0.89%
Net expense ratio1.34%
Sales charges
Max front load0.00%
Max deferred load1.00%
Redemption fee—
Expense limitation in place (N-CEN)Yes
Fees waived or reduced during the yearYes
Waived fees subject to recoupmentNo

C000156862 Costs Over Time

On $10,000 invested in C000156862, assuming 5% a year before costs, total costs come to $847 over 5 years, cutting the return by 1.43% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).

$10,000 investedSell after 1 yearSell after 3 yearsSell after 5 years
Value before costs$10,500$11,576$12,763
Sales charges$104$0$0
Fund expenses (net expense ratio 1.34%)$141$437$756
Trading costs (broker commissions)$3$8$14
Lost growth on money paid in costs$0$22$78
Total costs$247$468$847
Value after costs$10,253$11,109$11,915
Impact on return, per year2.47%1.43%1.43%

C000156862 Trading Costs

Brokerage costs reported on SEC Form N-CEN for the fiscal year ending February 28, 2023.

  • Explicit cost rate (commissions ÷ average net assets): 0.0247%
  • Total broker commissions: $4K
  • Bought from dealers (principal trades, not a cost): —
  • Portfolio turnover (prospectus): 87%
  • Securities lending: none during the year

C000156862 Agency Brokers

Commissions paid.

BrokerAmountShare
Goldman Sachs & Co. LLC$4K100.00%

For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.